80 Micrograms for Schizophrenia
Study Summary
This trial shows that BXCL501 is safe and effective in treating children and adolescents with bipolar disorder or schizophrenia who are experiencing acute agitation.
- Schizophrenia
- Schizoaffective Disorder
- Bipolar Disorder
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Have any other trials been conducted to assess the efficacy of BXCL501?
"Currently, there are 110 clinical trials evaluating the efficacy of BXCL501 with 23 studies in their last phase. Most of these tests take place in Karachi, Sindh though there exist 207 sites across the world running this medication's research."
Who is eligible to take part in this medical experiment?
"This schizophrenia study requires 140 minors between the ages of 10 and 17. Inclusion criteria include a total score of at least 14 on the PANSS Excited Component (PEC) during screening and baseline, an agreement to use reliable birth control methods, as well as a score greater than 4 on one or more PEC items at Baseline."
How many medical institutions are engaged in executing this experiment?
"At the moment, this clinical trial is being conducted at 6 different sites. These can be found in Orem, Atlanta and Hialeah as well as 3 other cities. To reduce travel requirements for participants it would make sense to pick a clinic that's closest to your location if you enroll."
Are there still openings available for volunteers to participate in this research endeavor?
"Indeed, according to clinicaltrials.gov, this research initiative is actively enrolling participants; its initial posting was on August 27th 2021 and the most recent update was September 26th 2022. The study seeks 140 volunteers at 6 separate facilities."
What medical issues is BXCL501 typically administered for?
"BXCL501 is a therapeutic agent used to manage the unsettling symptoms of diseases like ventilations, mechanical, and cyclic vomiting syndrome."
Has BXCL501 been given the go-ahead by the Food and Drug Administration?
"Due to the limited amount of evidence available for its safety and efficacy, BXCL501 received a score of 1."
What is the upper bound of participants in this research endeavor?
"Affirmative. This trial is looking for volunteers, and the information found on clinicaltrials.gov confirms this fact. It was first posted in August of 2021 and its most recent update was from September 2022. The experiment needs 140 patients to be recruited from 6 different research centres."
Does the eligibility criteria for this experiment extend to persons aged 40 and above?
"This trial is targeting individuals aged 10 to 17. On clinicaltrials.gov, there are 367 studies open for minors and 911 trials available to senior citizens above 65 years of age."